Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed evolving from symptom‐based strategies to others aiming to move patients to low‐risk conditions. Endothelin‐1 (ET‐1) receptor antagonists emerged as specific‐PAH drugs th...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldalaan, Abdullah M., Saleemi, Sarfraz A., Weheba, Ihab, Abdelsayed, Abeer, Aleid, Maha M., Alzubi, Fatima, Zaytoun, Hamdeia, Alharbi, Nadeen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063971/
https://www.ncbi.nlm.nih.gov/pubmed/35514768
http://dx.doi.org/10.1002/pul2.12083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063971/
https://www.ncbi.nlm.nih.gov/pubmed/35514768
http://dx.doi.org/10.1002/pul2.12083

Ejemplares similares